Search





Search





Markets
/
Stocks
/
tcrx
/

TScan Therapeutics Inc

TCRX

Add to Watchlist

0.743USD

-0.013-1.68%

Close 07-31 16:00（ET）Quotes delayed by 15 min

42.28MMarket Cap

LossP/E TTM

TScan Therapeutics Inc

0.743

-0.013-1.68%

Financial Summary Income Statement Balance Sheet Cash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial Summary Income Statement Balance Sheet Cash Flow Statement

TCRX Cash Flow Statement

You can access the annual and quarterly cash flow statements of TScan Therapeutics Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

FY2021Q2

FY2021Q1

FY2020Q4

FY2020Q3

FY2020Q2

FY2020Q1

Operating cash flows (indirect method)

Cash flow from continuing operating activities

35.40%-24.28M

-16.74%-32.00M

-16.28%-32.46M

-26.85%-33.27M

-28.42%-37.59M

-15.34%-27.41M

-448.24%-27.92M

-19.09%-26.23M

-24.08%-29.27M

-48.44%-23.77M

147.15%8.02M

-64.75%-22.02M

-17.21%-23.59M

-11.34%-16.01M

-24.65%-17.00M

-24.93%-13.37M

-102.11%-20.12M

-95.65%-14.38M

-135.62%-13.64M

-170.19%-10.70M

-94.13%-9.96M

---7.35M

---5.79M

--15.24M

---5.13M

Net income from continuing operations

16.00%-28.67M

35.83%-22.98M

-19.48%-35.71M

-16.71%-36.95M

-13.22%-34.13M

-82.58%-35.81M

-29.96%-29.89M

-31.67%-31.66M

-33.59%-30.14M

-4.75%-19.61M

-41.56%-23.00M

-59.27%-24.05M

-39.66%-22.56M

-31.85%-18.72M

-2.56%-16.25M

-41.44%-15.10M

-104.20%-16.16M

-81.89%-14.20M

-120.91%-15.84M

-90.17%-10.67M

-42.89%-7.91M

---7.81M

---7.17M

---5.61M

---5.54M

Operating gains losses

2.21%693.00K

1.69%723.00K

-25.32%767.00K

-37.46%698.00K

-45.93%678.00K

-44.45%711.00K

-20.14%1.03M

-13.89%1.12M

-16.34%1.25M

-13.75%1.28M

2.80%1.29M

7.37%1.30M

25.44%1.50M

29.95%1.48M

18.47%1.25M

82.60%1.21M

154.80%1.20M

188.38%1.14M

205.20%1.06M

148.50%661.00K

111.26%469.00K

--396.00K

--346.00K

--266.00K

--222.00K

Other non-cash items

100.00%0.00

88.04%-55.00K

80.61%-291.00K

-100.00%-786.00K

-181.90%-1.28M

45.04%-460.00K

-538.72%-1.50M

---393.00K

---453.00K

---837.00K

---235.00K

----

Change in working capital

117.37%1.11M

-324.78%-11.82M

-28.67%-359.00K

-82.32%386.00K

-202.70%-6.38M

184.85%5.26M

-100.98%-279.00K

407.03%2.18M

45.70%-2.11M

-2082.39%-6.20M

961.10%28.40M

-41.92%-711.00K

36.81%-3.88M

86.51%-284.00K

-1378.29%-3.30M

57.90%-501.00K

-115.08%-6.15M

-2214.29%-2.11M

-71.52%258.00K

-105.81%-1.19M

-3910.67%-2.86M

---91.00K

--906.00K

--20.47M

--75.00K

-Change in receivables

----

--31.93M

---31.93M

----

-Change in prepaid expenses

124.05%126.00K

-329.19%-903.00K

173.98%867.00K

333.33%35.00K

-305.49%-524.00K

904.08%394.00K

-68.88%-1.17M

-100.52%-15.00K

121.61%255.00K

-102.46%-49.00K

53.86%-694.00K

140.33%2.91M

43.97%-1.18M

350.23%1.99M

-83.86%-1.50M

180.61%1.21M

-193.31%-2.11M

143.50%442.00K

-389.82%-818.00K

-1237.12%-1.50M

-366.23%-718.00K

---1.02M

---167.00K

--132.00K

---154.00K

-Change in other current liabilities

54.77%-982.00K

-285.44%-2.57M

-139.47%-2.51M

-475.84%-3.08M

-283.57%-2.17M

90.76%-666.00K

73.00%-1.05M

-101.99%-534.00K

85.39%-566.00K

-250.39%-7.21M

-73.59%-3.88M

1095.00%26.86M

-90.09%-3.87M

-8.09%-2.06M

-49.70%-2.24M

-47.33%-2.70M

-56.17%-2.04M

-423.08%-1.90M

-678.65%-1.50M

-109.16%-1.83M

---1.30M

---364.00K

---192.00K

--20.00M

--0.00

Cash from non-recurring investing activities

Cash from operating activities

35.40%-24.28M

-16.74%-32.00M

-16.28%-32.46M

-26.85%-33.27M

-28.42%-37.59M

-15.34%-27.41M

-448.24%-27.92M

-19.09%-26.23M

-24.08%-29.27M

-48.44%-23.77M

147.15%8.02M

-64.75%-22.02M

-17.21%-23.59M

-11.34%-16.01M

-24.65%-17.00M

-24.93%-13.37M

-102.11%-20.12M

-95.65%-14.38M

-135.62%-13.64M

-170.19%-10.70M

-94.13%-9.96M

---7.35M

---5.79M

--15.24M

---5.13M

Investing cash flow

Net cash from continuing investing activities

-95.43%70.00K

-80.74%171.00K

4.01%1.43M

48.38%1.28M

117.30%1.53M

89.34%888.00K

-3.45%1.37M

105.24%862.00K

-15.87%705.00K

-65.94%469.00K

234.67%1.42M

-77.81%420.00K

57.82%838.00K

-37.72%1.38M

-50.29%424.00K

-51.68%1.89M

-82.05%531.00K

59.64%2.21M

-36.49%853.00K

1113.00%3.92M

149.28%2.96M

--1.39M

--1.34M

--323.00K

--1.19M

Capital expenditures

-95.43%70.00K

-80.74%171.00K

4.01%1.43M

48.38%1.28M

117.30%1.53M

89.34%888.00K

-3.45%1.37M

105.24%862.00K

-15.87%705.00K

-65.94%469.00K

234.67%1.42M

-77.81%420.00K

57.82%838.00K

-37.72%1.38M

-50.29%424.00K

-51.68%1.89M

-82.05%531.00K

59.64%2.21M

-36.49%853.00K

1113.00%3.92M

149.28%2.96M

--1.39M

--1.34M

--323.00K

--1.19M

Net cash flow from disposal of fixed assets

-95.43%70.00K

-80.74%171.00K

4.01%1.43M

48.38%1.28M

117.30%1.53M

89.34%888.00K

-3.45%1.37M

105.24%862.00K

-15.87%705.00K

-65.94%469.00K

234.67%1.42M

-77.81%420.00K

57.82%838.00K

-37.72%1.38M

-50.29%424.00K

-51.68%1.89M

-82.05%531.00K

59.64%2.21M

-36.49%853.00K

1113.00%3.92M

149.28%2.96M

--1.39M

--1.34M

--323.00K

--1.19M

Net cash flow from investment products

-100.00%0.00

-46.77%15.00M

141.98%34.00M

251.32%49.72M

-59.15%15.06M

1083.08%28.18M

-34.98%-80.98M

---32.85M

--36.87M

--2.38M

---59.99M

----

Net cash flow from other investing activities

----

--1.00K

----

Cash from non-current investing activities

Net cash flow from investing activities

-100.52%-70.00K

-45.67%14.83M

139.56%32.58M

243.66%48.44M

-62.59%13.53M

1326.71%27.29M

-34.09%-82.35M

-7927.62%-33.72M

4415.39%36.16M

238.93%1.91M

-14384.43%-61.41M

77.81%-420.00K

-57.82%-838.00K

37.72%-1.38M

50.29%-424.00K

51.68%-1.89M

82.05%-531.00K

-59.64%-2.21M

36.49%-853.00K

-1113.00%-3.92M

-149.28%-2.96M

---1.39M

---1.34M

---323.00K

---1.19M

Financing cash flow

Cash flow from continuous financing activities

100.00%0.00

-99.84%73.00K

-100.00%0.00

-99.93%116.00K

-303.49%-525.00K

240373.68%45.69M

588.10%1.23M

19.10%161.59M

--258.00K

-82.41%19.00K

-100.87%-252.00K

437564.52%135.68M

-100.00%0.00

-10.00%108.00K

-67.85%29.13M

104.52%31.00K

-99.91%88.00K

200.00%120.00K

9060700.00%90.61M

-2738.46%-686.00K

44979.64%99.63M

--40.00K

--1.00K

--26.00K

--221.00K

Net cash flow from debt Issuance/repayment

----

-100.00%0.00

----

--15.31M

----

--0.00

----

--0.00

--29.35M

----

Net cash flow from common stock issuance/repurchase

----

--0.00

100.00%0.00

-22.23%33.13M

----

--0.00

---186.00K

--42.60M

----

--0.00

----

--0.00

--89.65M

----

Net cash flow from preferred stock issuance/repurchase

----

--0.00

-100.00%0.00

--0.00

--99.73M

--0.00

----

--0.00

Proceeds from stock option exercised by employees

----

-80.69%73.00K

-100.00%0.00

3.80%191.00K

----

1889.47%378.00K

12200.00%1.23M

-73.02%184.00K

--258.00K

111.11%19.00K

100.00%10.00K

2100.00%682.00K

-100.00%0.00

-92.50%9.00K

400.00%5.00K

-50.00%31.00K

-18.52%88.00K

200.00%120.00K

0.00%1.00K

138.46%62.00K

-51.13%108.00K

--40.00K

--1.00K

--26.00K

--221.00K

Proceeds from issuance of warrants

----

--30.00M

100.00%0.00

38.83%128.27M

----

--0.00

---76.00K

--92.39M

----

Net cash flow from other financing activities

100.00%0.00

--0.00

---75.00K

---525.00K

----

-100.00%0.00

----

--99.00K

-123.96%-230.00K

100.00%0.00

----

--960.00K

---748.00K

---212.00K

----

--0.00

Net cash from non-recurrent financing activities

Net cash from financing activities

100.00%0.00

-99.84%73.00K

-100.00%0.00

-99.93%116.00K

-303.49%-525.00K

240373.68%45.69M

588.10%1.23M

19.10%161.59M

--258.00K

-82.41%19.00K

-100.87%-252.00K

437564.52%135.68M

-100.00%0.00

-10.00%108.00K

-67.85%29.13M

104.52%31.00K

-99.91%88.00K

200.00%120.00K

9060700.00%90.61M

-2738.46%-686.00K

44979.64%99.63M

--40.00K

--1.00K

--26.00K

--221.00K

Net cash flow

Beginning cash balance

-14.31%157.44M

26.34%174.54M

-29.44%174.43M

9.34%159.14M

32.76%183.72M

-13.78%138.15M

15.58%247.19M

44.62%145.54M

10.66%138.39M

12.56%160.22M

63.71%213.87M

-31.01%100.64M

-24.86%125.06M

-22.18%142.34M

22.33%130.64M

19.47%145.87M

370.34%166.44M

314.93%182.91M

108.53%106.79M

236.69%122.10M

-16.46%35.39M

--44.08M

--51.21M

--36.26M

--42.36M

Current period cash flow changes

0.94%-24.35M

-137.52%-17.10M

100.10%112.00K

-84.96%15.29M

-443.60%-24.58M

308.72%45.57M

-103.25%-109.04M

-10.23%101.65M

129.29%7.15M

-26.36%-21.83M

-558.42%-53.65M

843.54%113.23M

-18.76%-24.43M

-4.91%-17.28M

-84.62%11.70M

0.49%-15.23M

-123.72%-20.57M

-89.43%-16.47M

1167.38%76.11M

-202.38%-15.30M

1522.64%86.71M

---8.70M

---7.13M

--14.95M

---6.09M

Ending cash balance

-16.37%133.09M

-14.31%157.44M

26.34%174.54M

-29.44%174.43M

9.34%159.14M

32.76%183.72M

-13.78%138.15M

15.58%247.19M

44.62%145.54M

10.66%138.39M

12.56%160.22M

63.71%213.87M

-31.01%100.64M

-24.86%125.06M

-22.18%142.34M

22.33%130.64M

19.47%145.87M

370.34%166.44M

314.93%182.91M

108.53%106.79M

236.69%122.10M

--35.39M

--44.08M

--51.21M

--36.26M

Free cash flow

37.75%-24.35M

-13.69%-32.17M

-15.71%-33.89M

-27.54%-34.55M

-30.52%-39.12M

-16.77%-28.30M

-543.89%-29.29M

-20.70%-27.09M

-22.71%-29.97M

-39.39%-24.23M

137.86%6.60M

-47.06%-22.44M

-18.25%-24.43M

-4.80%-17.39M

-20.24%-17.43M

-4.39%-15.26M

-59.92%-20.66M

-89.94%-16.59M

-103.21%-14.49M

-197.96%-14.62M

-104.50%-12.92M

---8.73M

---7.13M

--14.92M

---6.32M

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did TScan Therapeutics Inc Generate?



TScan Therapeutics Inc generated -135.32M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did TScan Therapeutics Inc's Operating Cash Flow Change Year Over Year?



TScan Therapeutics Inc's operating cash flow increased by -22.10% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does TScan Therapeutics Inc Spend on Capital Expenditures?



TScan Therapeutics Inc spent 4.41M on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has TScan Therapeutics Inc's Financing Cash Flow Changed?



TScan Therapeutics Inc used -336.00K in financing activities in the latest quarter.

What is free cash flow and why does it matter for TCRX?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was TScan Therapeutics Inc’s free cash flow in the latest quarter?



Free cash flow was -139.73M reflecting a -21.87% change from the previous year.